[1]宋养荣,程 蒿,刘 佳,等.Ⅲ期食管癌新辅助化疗后行腔镜手术治疗临床研究[J].陕西医学杂志,2021,50(11):1358-1361.[doi:DOI:10.3969/j.issn.1000-7377.2021.11.009]
　SONG Yangrong,CHENG Hao,LIU Jia,et al.Clinical efficacy of endoscopic surgery after neoadjuvant chemotherapy for stage Ⅲ esophageal cancer[J].,2021,50(11):1358-1361.[doi:DOI:10.3969/j.issn.1000-7377.2021.11.009]
点击复制

Ⅲ期食管癌新辅助化疗后行腔镜手术治疗临床研究
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
50
期数:
2021年11期
页码:
1358-1361
栏目:
临床研究
出版日期:
2021-11-05

文章信息/Info

Title:
Clinical efficacy of endoscopic surgery after neoadjuvant chemotherapy for stage Ⅲ esophageal cancer
作者:
宋养荣; 程 蒿; 刘 佳; 强 准; 张新伟
(陕西省肿瘤医院胸外科,陕西 西安 710061)
Author(s):
SONG Yangrong; CHENG Hao; LIU Jia; QIANG Zhun; ZHANG Xinwei
(Department of Thoracic Surgery,Shaanxi Provincial Cancer Hospital,Xi'an 710061,China)
关键词:
Ⅲ期食管癌;  新辅助化疗;  腔镜手术;  生活质量;  生存曲线
Keywords:
Stage Ⅲ esophageal cancer;  Neoadjuvant chemotherapy;  Endoscopic surgery;  Quality of life;  Survival curve
分类号:
R 735.1
DOI:
DOI:10.3969/j.issn.1000-7377.2021.11.009
文献标志码:
A
摘要:
目的:探讨Ⅲ期食管癌新辅助化疗后行腔镜手术的临床疗效。方法:收集收治的Ⅲ期食管癌患者的临床资料。新辅助化疗后行腔镜手术者38例,设为观察组; 单纯行腔镜手术者45例,设为对照组。比较两组患者围术期指标(手术时间、术中出血量、胸管留置时间、淋巴结清扫数目、淋巴结转移率)、近期疗效、术后并发症(吻合口瘘或狭窄、喉返神经损伤、肺部感染、心率失常)发生率、复发率和1年生存率、中位生存时间,观察治疗前后生活质量[食管癌专用生活质量量表(QLQ-OES18)]变化情况。结果:两组患者手术时间、术中出血量、胸管留置时间、淋巴结清扫数目、术后并发症发生率比较差异无统计学意义(均P>0.05); 观察组患者淋巴结转移率低于对照组,近期治疗总有效率高于对照组,术后复发率低于对照组,1年生存率高于对照组(均P<0.05),中位生存时间为32个月,高于对照组17个月(P<0.05); 术后3个月,两组患者吞咽功能评分较术前升高,且观察组高于对照组(P<0.05),进食不适、反流、疼痛、吞咽梗阻、口干、咽口水困难、食欲减退、咳嗽、言语等症状评分均较术前降低,且观察组低于对照组(均P<0.05)。结论:新辅助化疗后行腔镜手术可提高Ⅲ期食管癌患者的手术根治率,减少淋巴结转移和术后复发率,改善生存率和生活质量。
Abstract:
Objective:To explore the clinical efficacy of endoscopic surgery after neoadjuvant chemotherapy for stage Ⅲ esophageal cancer.Methods:The clinical data of patients with stage Ⅲ esophageal cancer were collected.38 patients who underwent endoscopic surgery after neoadjuvant chemotherapy were set as observation group,and 45 patients who underwent endoscopic surgery alone were set as control group.Perioperative indicators(surgery time,intraoperative blood loss,chest tube indwelling time,number of lymph node dissection,lymph node metastasis rate),short-term efficacy,incidence rates of postoperative complications(anastomotic fistula or stenosis,recurrent laryngeal nerve injury,lung infection,arrhythmia),recurrence rate,1-year survival rate and median survival time were compared between the two groups.The quality of life(QLQ-OES18)was observed before and after treatment.Results:There were no significant differences in the surgery time,intraoperative blood loss,chest tube indwelling time,number of lymph node dissection and incidence rates of postoperative complications between the two groups(all P>0.05).The lymph node metastasis rate in observation group was lower than that in control group,and the total effective rate of short-term treatment was higher than that in control group,and the postoperative recurrence rate was lower than that in control group,and the 1-year survival rate was higher than that in control group(all P<0.05); the median survival time was higher than that in control group(32 months vs.17 months,P<0.05).At 3 months after surgery,the swallowing function scores in the two groups were higher than those before surgery,and the score in observation group was higher than that in control group(all P<0.05); the scores of symptoms of eating discomfort,reflux,pain,swallowing obstruction,dry mouth,swallowing difficulty,loss of appetite,cough and speech were lower than those before surgery,and the scores in observation group were lower than those in control group(all P<0.05).Conclusion:Endoscopic surgery after neoadjuvant chemotherapy can improve the surgical cure rate of paients with stage Ⅲ esophageal cancer,reduce lymph node metastasis and postoperative recurrence,and improve survival rate and quality of life.

参考文献/References:

[1] 张 涛,王 波.碘-125放射性粒子覆膜支架置入对晚期食管癌的有效性与安全性分析[J].实用癌症杂志,2018,33(2):283-286.
[2] 马东阳,周浩本,杨 峰,等.中药配合放射治疗中晚期食管癌30例[J].陕西中医,2008,29(1):12-13.
[3] 肖文刚,陈小艳,李小江.中药联合放疗对食管癌患者近期疗效及生活质量的影响[J].陕西中医,2016,37(7):850-851.
[4] 许俐文,丁 婷,姚晓丹,等.IMRT联合TP方案治疗局部晚期食管鳞癌疗效及安全性研究[J].实用癌症杂志,2018,33(4):602-605.
[5] 王聿明,钱晓哲,曹子昂,等.高龄食管癌患者手术治疗的预后分析[J].上海交通大学学报:医学版,2017,37(7):1020-1024.
[6] 冉 刚,周丽珍,周 超,等.局部中晚期食管癌术前新辅助放化疗联合食管癌根治术的临床研究[J].中华放射肿瘤学杂志,2017,26(8):874-879.
[7] 杨学宁,吴一龙.实体瘤治疗疗效评价标准—RECIST[J].循证医学,2004,4(2):85-90.
[8] 李惠霞,杨 华,郎文静,等.量表EORTC QLQ-OES18在中国食管癌患者中的有效性验证[J].重庆医学,2016,45(21):2969-2972.
[9] 马海龙,张 勇,邱春丽,等.中国西北地区食管癌患者照顾者生存质量及影响因素分析[J].陕西医学杂志,2016,45(2):245-247.
[10] 卿瑞辰,王 睿,陈焕文,等.胸腹腔镜与传统开胸手术对食管癌患者术后炎症因子的影响[J].第三军医大学学报,2017,39(23):2303-2306.
[11] 王 军,魏 洁,江海峰,等.Ⅲ期老年胸段食管癌术后放疗与同步放化疗临床疗效对比研究[J].陕西医学杂志,2018,47(12):1568-1571,1575.
[12] Nakatani M,Migita K,Matsumoto S,et al.Prognostic significance of the prognostic nutritional index in esophageal cancer patients undergoing neoadjuvant chemotherapy[J].Diseases of the Esophagus,2017,30(8):1-7.
[13] 魏晓华,郭俊霞.不同内镜技术在食管癌及癌前病变筛查中的应用价值研究[J].陕西医学杂志,2019,48(5):591-594.
[14] Miyata H,Sugimura K,Motoori M,et al.Clinical assessment of sarcopenia and changes in body composition during neoadjuvant chemotherapy for esophageal cancer[J].Anticancer Research,2017,37(6):3053.
[15] Motoori M,Yano M,Miyata H,et al.Randomized study of the effect of synbiotics during neoadjuvant chemotherapy on adverse events in esophageal cancer patients[J].Clinical Nutrition,2017,36(1):93-99.
[15] 史燕杰,陈 颖,李晓婷,等.多排CT评价局部进展期食管鳞癌新辅助化疗后再分期及疗效[J].中国医学科学院学报,2017,39(1):133-139.
[17] 李晓宁,徐志宏,王 涛.紫杉醇联合顺铂与顺铂联合5-氟尿嘧啶同步放疗治疗局部中晚期食管癌的疗效及安全性评价[J].中国地方病防治杂志,2017,32(6):618-618.
[18] 顾海娟,朱冬梅,倪静怡,等.治疗药物监测在晚期食管癌多西他赛联合奈达铂化疗中的应用价值[J].中华肿瘤防治杂志,2017,24(3):192-195.
[19] 吴 瑾,周莉华,齐立伟.多西他赛与奈达铂联合放疗对老年食管癌患者血清指标及肿瘤循环细胞的影响[J].中国老年学杂志,2018,38(24):5949-5952.
[20] 郑 浩,汪 灏,唐 汉,等.新辅助同步放化疗与新辅助化疗治疗局部进展期食管鳞癌的疗效分析[J].中华消化外科杂志,2017,16(5):464-468.

相似文献/References:

[1]韩丕华,袁 权△.乳腺癌患者白细胞介素-22表达水平对新辅助化疗后病理学完全缓解的预测价值*[J].陕西医学杂志,2020,49(7):889.[doi:DOI:10.3969/j.issn.10007377.2020.07.033]
　HAN Pihua,YUAN Quan..Predictive value of IL-22 expression level in breast cancer patients for pathological complete remission after neoadjuvant chemotherapy[J].,2020,49(11):889.[doi:DOI:10.3969/j.issn.10007377.2020.07.033]
[2]钟 亮,廖荣伟,刘清壮,等.调强适形放疗联合新辅助化疗治疗上下行型鼻咽癌疗效研究*[J].陕西医学杂志,2020,49(8):964.[doi:DOI:10.3969/j.issn.1000-7377.2020.08.013]
　ZHONG Liang,LIAO Rongwei,LIU Qingzhuang,et al.Effect of intensity-modulated radiotherapy combined with neoadjuvant chemotherapy in treatment of ascending and descending types of nasopharyngeal carcinoma[J].,2020,49(11):964.[doi:DOI:10.3969/j.issn.1000-7377.2020.08.013]
[3]张新伟,王瑞洁,张 曦,等.帕博利珠单抗联合新辅助化疗治疗Ⅱ、Ⅲ期食管癌临床疗效[J].陕西医学杂志,2022,51(7):870.[doi:DOI:10.3969/j.issn.1000-7377.2022.07.025]
　ZHANG Xinwei,WANG Ruijie,ZHANG Xi,et al.Clinical efficacy of pembrolizumab combined with neoadjuvant chemotherapy in treatment of stage Ⅱ and Ⅲ esophageal cancer[J].,2022,51(11):870.[doi:DOI:10.3969/j.issn.1000-7377.2022.07.025]
[4]薛 昭,张卓红.肺癌新辅助化疗患者血清C-反应蛋白、降钙素原和细胞角蛋白19片段抗原表达与肺部感染严重程度评分关系[J].陕西医学杂志,2022,51(10):1227.[doi:DOI:10.3969/j.issn.1000-7377.2022.10.012]
　XUE Zhao,ZHANG Zhuohong.Correlation between expression levels of serum CRP,PCT,CYFRA21-1 and severity score of pulmonary infection in patients with lung cancer undergoing neoadjuvant chemotherapy[J].,2022,51(11):1227.[doi:DOI:10.3969/j.issn.1000-7377.2022.10.012]
[5]崔 杰,刘 鑫.纤维蛋白原与白蛋白比值与激素受体阳性/人类表皮生长因子受体2阴性乳腺癌新辅助化疗疗效相关性分析[J].陕西医学杂志,2022,51(11):1351.[doi:DOI:10.3969/j.issn.1000-7377.2022.11.007]
　CUI Jie,LIU Xin.Correlation between fibrinogen to albumin ratio and efficacy of neoadjuvant chemotherapy for hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer[J].,2022,51(11):1351.[doi:DOI:10.3969/j.issn.1000-7377.2022.11.007]
[6]裴彦江,戚 斌.术前替吉奥联合奥沙利铂新辅助化疗治疗SiewertⅡ型食管胃结合部腺癌临床疗效研究[J].陕西医学杂志,2022,51(11):1420.[doi:DOI:10.3969/j.issn.1000-7377.2022.11.024]
[7]王玉龙,张美荣,周 昱.乳腺癌患者血清微小RNA-135b、微小RNA-148a-3p、微小RNA-186-5p表达水平及其与新辅助化疗效果相关性研究[J].陕西医学杂志,2024,(5):684.[doi:DOI:10.3969/j.issn.1000-7377.2024.05.024]
　WANG Yulong,ZHANG Meirong,ZHOU Yu.Levels of serum miR-135b,miR-148a-3p and miR-186-5p in breast cancer patients and their correlation with the effect of neoadjuvant chemotherapy[J].,2024,(11):684.[doi:DOI:10.3969/j.issn.1000-7377.2024.05.024]
[8]周永安,阮 勇.白蛋白结合型紫杉醇与多西紫杉醇在人表皮生长因子受体-2阳性乳腺癌患者新辅助化疗中的疗效对比研究[J].陕西医学杂志,2024,(9):1236.[doi:DOI:10.3969/j.issn.1000-7377.2024.09.018]
　ZHOU Yongan,RUAN Yong.Efficacy of albumin-bound paclitaxel and docetaxel in neoadjuvant chemotherapy of patients with HER2-positive breast cancer[J].,2024,(11):1236.[doi:DOI:10.3969/j.issn.1000-7377.2024.09.018]

备注/Memo

备注/Memo:
基金项目:陕西省科技计划项目(2020SF-289)
更新日期/Last Update: 2021-11-05